Palatin Technologies Presents Compelling Preclinical Data on Next-Generation MC4R-Selective Peptide Agonists at ObesityWeek® 2026
Palatin Technologies presented new preclinical data at ObesityWeek 2026 showing its next-generation MC4R-selective peptide agonists deliver potent weight-loss activity with minimal to no MC1R activity. The selectivity (over 100- to 200-fold for MC4R over MC1R) supports the goal of reducing or eliminating hyperpigmentation, a known limitation of approved MC4R therapies, while its lipidation technology enables once-weekly or less frequent dosing.
Key figures
- Drug Name
- PL2001
- Phase Of Trial
- Preclinical (first-in-human targeted H1 2027)
- Dog half life lipidated
- greater than 168 hours
- Non lipidated half life
- approximately two hours
- Mc4r over mc1r selectivity
- greater than 100-fold to greater than 200-fold
- Rodent half life lipidated
- approximately 24 hours
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.